ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer ...

Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early ...

Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting ...

Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types

Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types ...
Everyday Health

10 Self-Care Tips to Help You Manage Immune Thrombocytopenia

While following any prescribed treatment is important, there are also vital steps you can take on your own to keep this blood disorder in check. Living with chronic immune thrombocytopenia (ITP), a ...
Lupus Science & Medicine

Clinical characteristics and prognostic factors in adult macrophage activation syndrome: an observational study in a Chinese cohort

Objective Macrophage activation syndrome (MAS), a subtype of secondary haemophagocytic lymphohistiocytosis (HLH), is a rare ...